Ipsen has reached an agreement to acquire privately held Kartos Therapeutics in a transaction that could total up to $1.75 billion, the French drugmaker said on Monday. The immediate payment to Kartos will be $450 million, with contingent additional payments of up to $1.3 billion linked to meeting regulatory and sales-related milestones.
The acquisition brings navtemadlin into Ipsen's late-stage oncology pipeline. Navtemadlin is currently advancing through late-stage clinical trials targeting myelofibrosis, a rare hematologic malignancy. Ipsen's management has framed the asset as a potential response to an identified care gap in this indication.
According to Ipsen, navtemadlin could emerge as a new treatment option as early as 2028. The company said the transaction should contribute to an increase in core operating profit from 2029 onward, while producing only a limited effect on its financial guidance for the current year.
The deal remains subject to customary closing conditions and is expected to be completed by the end of the third quarter. No additional financial details beyond the upfront and milestone structure were provided in the announcement.
Context and implications
For Ipsen, the purchase is an acquisition of late-stage clinical proof-of-concept in oncology, bringing an asset that could, if clinical and regulatory paths proceed as anticipated, expand the company's treatment options for patients with myelofibrosis. The structure of the transaction - a sizable upfront payment plus milestone-driven contingent consideration - ties a material portion of the total value to future clinical, regulatory, and commercial outcomes.
Financial timing
Ipsen has signaled that the deal will be earnings-accretive from 2029. In the near term, the company expects this transaction to have only a limited impact on its guidance for the current fiscal year.
Regulatory and closing considerations
The acquisition is conditioned on customary closing steps and the realization of regulatory and sales milestones that will determine the contingent payments. The timeline for potential market availability of navtemadlin was described by Ipsen as possibly beginning in 2028, pending the outcomes of the ongoing late-stage trials and subsequent regulatory reviews.